ClinicalTrials.gg
RecruitingNCT06583733KOKU BladderUpdated Mar 30, 2025

Keep On Keep Up Bladder Health: Co-creating and Testing a Self-management Technological Solution for Ageing Well

An interventional study of KOKU Bladder and recommendations in Urinary Incontinence in Old Age, sponsored by University of Vic - Central University of Catalonia. Recruiting at 4 sites in 3 countries. Open to participants aged 50 Years to 100 Years. Per ClinicalTrials.gov, last updated 2025-03-30.

Sponsored by University of Vic - Central University of Catalonia · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
50 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 56 studies in Urinary Incontinence with a site in Spain — 12 open to participants now, 13 under way, none of them phase 3. Urinary Incontinence · Spain.

Planned enrollment
21st of 46
120 · median 113
Started
2025
with 3 others
No phase
28 of 56
7 open now
Primary completion
2027-08
later than 9 of 12 live
Registered
45th of 56
by date

Among the 56 studies in Urinary Incontinence with a site in Spain, this one is the 21st largest by planned enrollment of the 46 interventional ones that give a count, is one of 4 that started in 2025, is one of 28 with no phase, reaches primary completion later than 9 of the 12 other live ones, and was the 45th registered.

Urinary Incontinence

988 studies on the registry are indexed under Urinary Incontinence; 184 are open to participants now.

Browse Urinary Incontinence studies →

Open to participants now

12 of the 56 studies in Urinary Incontinence with a site in Spain are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 113 Urinary Incontinence studies recruiting now, 63 (56%) set no upper age limit and 35 (31%) stop at 75 or younger; 15 take children under 18; 28 take healthy volunteers.

This study: 50 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies in Urinary Incontinence with a site in Spain, or all of them as a file.
02

Study summary

KOKU Bladder aims to develop and test an evidence based digital health program with behavior change techniques to improve bladder health of adults aged 50 and over. A novel module embedded in the approved app "Keep-on-Keep-up" (KOKU) will be co-created with end-users, researchers, health professionals, and stakeholders through a participatory and appreciative action and reflection methodology. After a comprehensive literature review and consultation with 4-6 experts, 6 focus groups will be undertaken in Kaunas(Lithuanian), Catalonia (Spain) and Manchester (UK) to co-create the contents of the module. Data will be analyzed using thematic analysis. Gamification and the Honeycomb model for user experience will be followed to achieve an appropriate technological solution that will be tested through a randomized controlled trial with at least 120 individuals. A mixed methods approach (quantitative/qualitative analysis) will be used to assess the feasibility and acceptability of the program. Open data and science, gender and ethical aspects, as well as a risk management plan are considered. A plan for communication, dissemination, exploitation of results will be considered. KOKU Bladder will be highly scalable and will have wide reach and impact. This proposal is in line with EU policy initiatives on Active and Healthy Ageing (bladder health and continence will be promoted), targeting aspects such as eHealth, Innovation and Digital Care Transformation, by supporting users to demand more responsive and integrated care programs for chronic conditions and enhancing self-management strategies, independence and health intelligence.

Read the detailed description

Phase I (month-M1-3): Prepare and submit protocol to Ethics Committee, conduct an updated review of the on eHealth solutions to manage UI using BCTs (e.g. training, education) that have been designed or tested in older adults, and establish contact with the Lithuanian, Spanish and UK participating institutions. Phase1 is dedicated to the management of the project throughout its duration.

Phase II (M2-5): Consultation with 4-6 experts on Badder Health (BH) and/or behavioral interventions. Develop a first iteration of the eHealth method and module.

Conduct an initial online focus group with 10-12 co-creators of UK to explore their perceived acceptability and feasibility and preferences for the eHealth program (concept development through co-creation).

Develop a first iteration of the eHealth method and module (concept development) - by Reason Digital (tech company in Manchester)

Phase III (M6-14): Organize, conduct and analyze 5 more focus group (2 in Lithuania, 1 UK and 2 Spain) with 10-12 co-creators each (community-dwelling people aged 50+ of both genders with different physical conditions and UI, health professionals and stakeholders with different backgrounds) to explore their perceived acceptability and feasibility and preferences for the eHealth program (concept development through co-creation). Secondment in University of Manchester.

Phase IV (M14-M20): Further develop the eHealth module (concept development) - by Reason Digital (tech company in Manchester)

Phase V (M21-36): Multicenter two-armed feasibility RCT study with at least 120 participants (WP3). Participants will be randomized to a control (recommendations for self- managing urinary symptoms) or intervention (KOKU Bladder) group.

Phase VI: Early and open communication and dissemination (WP4). Analysis of results.

03

Conditions studied

  • Urinary Incontinence in Old Age

Keywords

  • pelvic health
  • urinary incontinence
  • aged
  • eHealth
  • behavior change
  • physical activity
  • sedentary behavior
  • bladder health
  • technology
04

Who can participate

Ages eligible
50 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥50 (range used in the literature covering the late-life process, including prostate issues and the perimenopause period)
  • Self-reported UI (at least 1 leakage/month)
  • Ability to read and understand the national languages
  • Have a mobile phone/tablet
  • Sign .

Exclusion criteria

Exclusion Criteria:

  • Red-flag symptoms (e.g., bleeding)
  • Unstable health conditions.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Active comparator
    control group

    The control group which will receive recommendations for self- managing urinary symptoms. There will be at least 60 participants (men and women mixed) distributed in 3 countries. It is anticipated that the multicomponent intervention will last 12 weeks. After the intervention we will collect the results with a mixed (qualitative and quantitative) approach.

    Behavioral: recommendations

  • Experimental
    intervention group

    The intervention group, which will receive the treatment with KOKU Bladder. There will be at least 60 participants (men and women mixed) distributed in 3 countries. It is anticipated that the multicomponent intervention will last 12 weeks. After the intervention we will collect the results with a mixed (qualitative and quantitative) approach.

    Behavioral: KOKU Bladder

Interventions

  • BehavioralKOKU Bladder

    In this intervention the participants will receive treatment with the KOKU app ( based digital health program with behavior change techniques to improve bladder health ) for 12 weeks. After the intervention we will collect the results with a mixed (qualitative and quantitative) approach. Qualitative information will be recorded and analysed through thematic analysis, and quantitative data will be collected with tests and questionnaires.

  • Behavioralrecommendations

    In this intervention the participants will receive recommendations for self- managing urinary symptoms, which they must follow for 12 weeks. After the intervention we will collect the results with a mixed (qualitative and quantitative) approach. Qualitative information will be recorded and analysed through thematic analysis, and quantitative data will be collected with tests and questionnaires.

06

What researchers measure

Primary outcomes

  1. To co-create, develop and test an evidence based digital health program with behavior change techniques to decrease UI of community-dwelling adults aged 50 and over

    The primary aim of KOKU Bladder is to co-create and test an eHealth program to address bladder health (specifically urinary incontinence) in community-dwelling adults aged 50 and over

    Time frame: 3 years

Secondary outcomes

  1. To evaluate the life-impact related to UI (Incontinence Impact Questionnaire-7) of community-dwelling adults aged 50 and over.

    We will use the Incontinence Impact Questionnaire-7 (IIQ-7) to assess it

    Time frame: 3 years

  2. To evaluate the lower urinary tract symptoms (International Prostate Symptom Score) of community-dwelling adults aged 50 and over.

    We will use different questionnaires.

    Time frame: 3 years

  3. To evaluate the Patient Global Impression of Improvement; SB (visual analogue scale, a 7-day recall period) of community-dwelling adults aged 50 and over

    We will use a visual analogue scale to assess it

    Time frame: 3 years

  4. To evaluate the satisfaction with treatment of community-dwelling adults aged 50 and over.

    We will use different questionnaires.

    Time frame: 3 years

  5. To modify the severity of UI (International Consultation on Incontinence Questionnaire-UI short form) of community-dwelling adults aged 50 and over

    We will use the International Incontinence Questionnaire-Short Form (ICIQ-SF) to assess it

    Time frame: 3 years

07

Study locations

3 of 4 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Aug 2027, 29 months after the start.

Of 303 non-industry interventional studies with no phase under Urinary Incontinence, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 37. This study's planned 29 months is above that.

Counting every sponsor, half of 366 studies reached it within 15 months; a quarter within 7 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2024
First posted
Sep 4, 2024
StartActual
Mar 24, 2025
Primary completionEst.
Aug 31, 2027
CompletionEst.
Oct 1, 2028
Last update
Mar 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06583733
Lead sponsor
University of Vic - Central University of Catalonia
Collaborators
Hospital Universitari Santa Maria de Lleida (GSS), Institut de Recerca i Innovació en Ciències de la Vida i de la Salut a la Catalunya Central (IRIS), University of Manchester, Research Council of Lithuania, Lithuanian Sports University, Agencia Gestió Ajuts Universitaris i Recerca, Consorci Hospitalari de Vic (CHV)
Responsible party
Javier Jerez Roig (Professor, Head of research group on Methodology, Methods, Models and Outcomes of Health and Social Science (M3O), University of Vic - Central University of Catalonia) — Principal investigator
First posted
Sep 4, 2024
Start date
Mar 24, 2025
Primary completion
Aug 31, 2027 (estimated)
Completion
Oct 1, 2028 (estimated)
Last update
Mar 30, 2025

Study contacts

Javier Jerez-Roig, Professor, PhD
Contact
javier.jerez@uvic.cat
+34 93 881 60 25
Jerez-Roig, PhD
principal investigator · University of Vic-Central University of Catalonia; Lithuanian Sports University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion